CoChat

The Coronavirus Disease 2019 Spatial Care Path: Home, Community, and Emergency Diagnostic Portals

Open access
Kost, Gerald J. · 2022 · Diagnostics

Published version of a preprint

The DOI matches its Crossref record; 109 of the 111 references it cites were found in a registry or an index.

Abstract

This research uses mathematically derived visual logistics to interpret COVID-19 molecular and rapid antigen test (RAgT) performance, determine prevalence boundaries where risk exceeds expectations, and evaluate benefits of recursive testing along home, community, and emergency spatial care paths. Mathematica and open access software helped graph relationships, compare performance patterns, and perform recursive computations. Tiered sensitivity/specificity comprise: (T1) 90%/95%; (T2) 95%/97.5%; and (T3) 100%/≥99%, respectively. In emergency medicine, median RAgT performance peaks at 13.2% prevalence, then falls below T1, generating risky prevalence boundaries. RAgTs in pediatric ERs/EDs parallel this pattern with asymptomatic worse than symptomatic performance. In communities, RAgTs display large uncertainty with median prevalence boundary of 14.8% for 1/20 missed diagnoses, and at prevalence > 33.3–36.9% risk 10% false omissions for symptomatic subjects. Recursive testing improves home RAgT performance. Home molecular tests elevate performance above T1 but lack adequate validation. Widespread RAgT availability encourages self-testing. Asymptomatic RAgT and PCR-based saliva testing present the highest chance of missed diagnoses. Home testing twice, once just before mingling, and molecular-based self-testing, help avoid false omissions. Community and ER/ED RAgTs can identify contagiousness in low prevalence. Real-world trials of performance, cost-effectiveness, and public health impact could identify home molecular diagnostics as an optimal diagnostic portal.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/diagnostics12051216

Cites

109 of 109 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Performance of rapid antigen testing in community settings. Predictive value geometric mean-squared (PV GM2) curves reflect performance (left vertical axis) over the entire range of prevalence (horizontal axis). RFO, the false omission rate (right axis), indicates the frequency of missed diagnoses. PV GM2 and RFO curves are plotted for low, median, and high sensitivity/specificity documented in published clinical studies conducted in community settings (see Supplementary Materials). Performance Tiers 1 and 2 are plotted in green. The black horizontal line represents a risk level of 5% where 1 in 20 diagnoses will be missed. A prevalence boundary (PB) is the point at which the risk of a missed diagnosis exceeds the threshold of 1 in 20, that is, the point at which risk of contagion rises significantly and quickly.
Figure 1 Performance of rapid antigen testing in community settings. Predictive value geometric mean-squared (PV GM2) curves reflect performance (left vertical axis) over the entire range of prevalence (horizontal axis). RFO, the false omission rate (right axis), indicates the frequency of missed diagnoses. PV GM2 and RFO curves are plotted for low, median, and high sensitivity/specificity documented in published clinical studies conducted in community settings (see Supplementary Materials). Performance Tiers 1 and 2 are plotted in green. The black horizontal line represents a risk level of 5% where 1 in 20 diagnoses will be missed. A prevalence boundary (PB) is the point at which the risk of a missed diagnosis exceeds the threshold of 1 in 20, that is, the point at which risk of contagion rises significantly and quickly.CC BY · PubMed Central
Figure 2 Comparison of symptomatic versus asymptomatic community rapid antigen testing performance based on evidence.
Figure 2 Comparison of symptomatic versus asymptomatic community rapid antigen testing performance based on evidence.CC BY · PubMed Central
Figure 3 Real-world performance of rapid antigen testing in emergency medicine.
Figure 3 Real-world performance of rapid antigen testing in emergency medicine.CC BY · PubMed Central
Figure 4 Comparison of symptomatic versus asymptomatic rapid antigen test performance in emergency medicine. The blue PV GM2 curves illustrate RAgT performance for pediatric patients presenting to emergency rooms (ERs) and emergency departments (EDs). The curves show that RAgTs are “unbalanced” in contrast to the design of the performance tiers. Please see the legend in the inset table for prevalence at points of best performance. For asymptomatic patients, performance falls off quickly as prevalence increases, which limits use in emergency medicine settings where, through self-selection by sick patients, one would expect prevalence to be higher than in the community. COVID-19 detection is more likely in symptomatic patients, in part because of higher viral loads.
Figure 4 Comparison of symptomatic versus asymptomatic rapid antigen test performance in emergency medicine. The blue PV GM2 curves illustrate RAgT performance for pediatric patients presenting to emergency rooms (ERs) and emergency departments (EDs). The curves show that RAgTs are “unbalanced” in contrast to the design of the performance tiers. Please see the legend in the inset table for prevalence at points of best performance. For asymptomatic patients, performance falls off quickly as prevalence increases, which limits use in emergency medicine settings where, through self-selection by sick patients, one would expect prevalence to be higher than in the community. COVID-19 detection is more likely in symptomatic patients, in part because of higher viral loads.CC BY · PubMed Central
Figure 5 Performance of rapid antigen testing for home self-testing based on manufacturer claims in FDA EUA authorizations. Theoretical analysis of manufacturer claims shows that repeat testing yields higher performance and prevalence boundaries. Median recursive performance achieves Tier 2. The median recursive prevalence boundary of 74.3% reflects a reasonable minimum for Omicron, BA.2, and other emerging variants and sub-variants.
Figure 5 Performance of rapid antigen testing for home self-testing based on manufacturer claims in FDA EUA authorizations. Theoretical analysis of manufacturer claims shows that repeat testing yields higher performance and prevalence boundaries. Median recursive performance achieves Tier 2. The median recursive prevalence boundary of 74.3% reflects a reasonable minimum for Omicron, BA.2, and other emerging variants and sub-variants.CC BY · PubMed Central
Figure 6 Performance of molecular diagnostics for home self-testing. In the case of home molecular diagnostics, one independent clinical evaluation, shown by the “CCE” curves, achieved Tier 1 performance.
Figure 6 Performance of molecular diagnostics for home self-testing. In the case of home molecular diagnostics, one independent clinical evaluation, shown by the “CCE” curves, achieved Tier 1 performance.CC BY · PubMed Central
Figure 7 False omission rate topology for asymptomatic and symptomatic subjects. The purple cluster shows performance for asymptomatic subjects in emergency medicine (EMA) and community (CA) settings, while the red cluster reflects results for symptomatic subjects. Saliva testing for asymptomatic subjects (SA, purple), with specimen collection at points of need and PCR analysis performed in laboratories, did not differ substantially from rapid antigen testing. “HMDx” represents one clinical evaluation of molecular self-testing, which achieved performance between Tier 1 and Tier 2. In this case the risk of a missed diagnosis (RFO) is 10%, shown by the red horizontal line.
Figure 7 False omission rate topology for asymptomatic and symptomatic subjects. The purple cluster shows performance for asymptomatic subjects in emergency medicine (EMA) and community (CA) settings, while the red cluster reflects results for symptomatic subjects. Saliva testing for asymptomatic subjects (SA, purple), with specimen collection at points of need and PCR analysis performed in laboratories, did not differ substantially from rapid antigen testing. “HMDx” represents one clinical evaluation of molecular self-testing, which achieved performance between Tier 1 and Tier 2. In this case the risk of a missed diagnosis (RFO) is 10%, shown by the red horizontal line.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 109 references

Research works printed but not linked: 3

  1. 4. Kost G.J., Ferguson W.J., Kost L.E. Principles of point of care culture, the spatial care path, and enabling community and global resilience. J. Int. Fed. Clin. Chem. Lab. Med. 2014;25:4–23.
  2. 5. Kost G.J., Ferguson W.J., Truong A.-T., Prom D., Hoe J., Banpavichit A., Kongpila S. The Ebola Spatial Care PathTM: Point-of-care lessons learned for stopping outbreaks. Clin. Lab. Int. 2015;39:6–14.
  3. 112. Eng M., Zadran A., Kost G.J. Covid-19 risk avoidance and management in limited-resource countries—Point-of-care strategies for Cambodia. Omnia Digital Health. June–July, 2021. [(accessed on 26 April 2022)]. pp. 112–115. Available online: https://secure.viewer.zmags.com/publication/44e87ae6?page=115&nocache=1625391874149&fbclid=IwAR2gIObRf6ThX15vlBpqMRYSC83hiZysJ8uMxEae7Em16bhOrnfEJTgNWuo#/44e87ae6/115.

Cited by

See all 13

Metadata

Authors
Kost, G. J.
Affiliations
University of California, Davis (US)
Corresponding author
Kost, Gerald J.
Venue
Diagnostics
Publisher
MDPI AG
Published
2022-05-12
Volume
12
Issue
5
Pages
1216
ISSN
2075-4418 (ISSN-L)
OpenAlex
W4280647568
Cited by
13
References
111
Citations by year
2025: 1 · 2024: 5 · 2023: 3 · 2022: 4
FWCI
1.59
Type
journal article
Language
en
Open access
Locations
  • Diagnostics (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Point-of-Care Testing Center for Teaching and Research (POCT•CTR)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
COVID-19 pandemic, rapid antigen test, molecular diagnosis, diagnostic performance, prevalence threshold, home testing, self-testing, emergency department testing, community-based testing, missed diagnosis, asymptomatic infection, saliva testing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Coronavirus Disease 2019 Spatial Care Path: Home, Community, and Emergency Diagnostic Portals. https://app.cochat.ai/papers/10.3390/diagnostics12051216
The paper
Kost, G. J. (2022). The Coronavirus Disease 2019 Spatial Care Path: Home, Community, and Emergency Diagnostic Portals. Diagnostics. https://doi.org/10.3390/diagnostics12051216

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.